LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

Search

Guardant Health Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

103.29 -2.37

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

99.21

Max

106.75

Pagrindiniai rodikliai

By Trading Economics

Pajamos

7.2M

-93M

Pardavimai

33M

265M

Pelno marža

-34.965

Darbuotojai

1,999

EBITDA

6.6M

-82M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+24.29% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-04-29

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

4.6B

14B

Ankstesnė atidarymo kaina

105.66

Ankstesnė uždarymo kaina

103.29

Naujienos nuotaikos

By Acuity

50%

50%

159 / 351 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Guardant Health Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-20 17:37; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Regulatory Waiting Period for Warner Bid Expires -- Update

2026-02-20 16:18; UTC

Pagrindinės rinkos jėgos

Footwear Stocks Rise After Supreme Court Strikes Down Tariffs

2026-02-20 23:12; UTC

Įsigijimai, susijungimai, perėmimai

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

2026-02-20 22:12; UTC

Uždarbis

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

2026-02-20 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-02-20 21:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-02-20 21:23; UTC

Uždarbis

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

2026-02-20 21:20; UTC

Rinkos pokalbiai

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

2026-02-20 21:01; UTC

Įsigijimai, susijungimai, perėmimai

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

2026-02-20 20:38; UTC

Rinkos pokalbiai

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

2026-02-20 20:17; UTC

Rinkos pokalbiai

Oil Futures Mixed As Market Awaits U.S.-Iran Moves -- Market Talk

2026-02-20 20:11; UTC

Rinkos pokalbiai

Traders Await Word on USMCA Exemption For Trump's Global 10% Tariff -- Market Talk

2026-02-20 19:59; UTC

Rinkos pokalbiai

U.S. Tariff Ruling Could Make Things Worse for Mexico -- Market Talk

2026-02-20 19:58; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Netflix Seen as Not Needing Warner Bros. Deal -- Market Talk

2026-02-20 19:49; UTC

Rinkos pokalbiai

Mexico's Revised 4Q GDP Expected to Confirm Pick-Up -- Market Talk

2026-02-20 19:09; UTC

Rinkos pokalbiai

Precious Metals Settle Higher After Tariff Ruling -- Market Talk

2026-02-20 19:00; UTC

Rinkos pokalbiai

U.S. Oil, Gas Rig Counts Unchanged on Week -- Market Talk

2026-02-20 18:28; UTC

Rinkos pokalbiai

Ontario Premier Warns Fight Against U.S. Tariffs Isn't Over -- Market Talk

2026-02-20 18:20; UTC

Rinkos pokalbiai

Tariff Ruling Seen Positive for Some Retailers, Mixed for Others -- Market Talk

2026-02-20 18:05; UTC

Rinkos pokalbiai

Market Talk Roundup: Latest on U.S. Politics

2026-02-20 18:04; UTC

Rinkos pokalbiai

Trade Uncertainty in Canada to Remain Until USMCA Resolved -- Market Talk

2026-02-20 17:38; UTC

Rinkos pokalbiai

Canada's Small Firms Look Toward Increased U.S. Tariff Opposition -- Market Talk

2026-02-20 17:24; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-02-20 17:24; UTC

Rinkos pokalbiai

Correction to Treasury Yields Fall Market Talk

2026-02-20 17:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-02-20 16:53; UTC

Rinkos pokalbiai

Market Talk Roundup: Latest on U.S. Politics

2026-02-20 16:53; UTC

Rinkos pokalbiai

Canada Dollar Steady, Market Focus on USMCA Review -- Market Talk

2026-02-20 16:45; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-02-20 16:45; UTC

Rinkos pokalbiai

U.K. Public Finances Supportive of Gilts in Near-Term -- Market Talk

2026-02-20 16:40; UTC

Rinkos pokalbiai

Trade Threats Facing Canada Not Removed by Supreme Court's Ruling -- Market Talk

Akcijų palyginimas

Kainos pokytis

Guardant Health Inc Prognozė

Kainos tikslas

By TipRanks

24.29% į viršų

12 mėnesių prognozė

Vidutinis 132.22 USD  24.29%

Aukščiausias 175 USD

Žemiausias 110 USD

Remiantis 20 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Guardant Health Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

20 ratings

19

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

38.86 / 47.41Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

159 / 351 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat